Related Experiment Video
Updated: May 30, 2026
05:58
Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate
Published on: June 25, 2019
Degludec insulin: A novel basal insulin
Sanjay Kalra1, Ambika Gopalakrishnan Unnikrishnan, Manash Baruah
1Department of Endocrinology, Bharti Hospital and BRIDE, Karnal, India.
Indian Journal of Endocrinology and Metabolism
|August 18, 2011
Summary
Insulin degludec shows promise as an ideal basal insulin, addressing limitations of current options. This review covers its pharmacology and clinical data for diabetes management.
Area of Science:
- Endocrinology
- Pharmacology
- Diabetes Mellitus Research
Background:
- Existing basal insulins and analogues have limitations impacting glycemic control and patient convenience.
- There is a continuous need for improved basal insulin therapies in diabetes management.
- Novel insulin formulations aim to provide more predictable pharmacokinetic profiles and reduced variability.
Purpose of the Study:
- To review the novel insulin analogue, insulin degludec, as a potential ideal basal insulin.
- To discuss the limitations of current basal insulins and the need for newer molecules.
- To assess the pharmacologic and clinical evidence for insulin degludec and insulin degludec plus.
Main Methods:
- Literature review of published pharmacologic and clinical studies on insulin degludec.
- Analysis of data regarding the pharmacokinetic and pharmacodynamic properties of insulin degludec.
- Evaluation of clinical trial outcomes, including efficacy, safety, and patient-reported benefits.
Main Results:
- Insulin degludec exhibits an ultra-long duration of action with a flat pharmacokinetic profile.
- Clinical studies demonstrate effective glycemic control with a low risk of hypoglycemia for insulin degludec.
- Insulin degludec offers potential advantages in flexibility of dosing and reduced mealtime insulin requirements.
Conclusions:
- Insulin degludec represents a significant advancement in basal insulin therapy.
- Its unique properties may offer improved treatment options for individuals with type 1 and type 2 diabetes.
- Further research and real-world data will continue to define the role of insulin degludec and degludec plus in clinical practice.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:27Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
01:25Insulin: Biosynthesis, Chemistry, and Preparation
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...